Dementia & Cognitive Disorders

Filter Your Results




The Digital Future of Cognitive Screening

With Douglas Scharre, MD

January/February 2017—As continued research elucidates Alzheimer’s disease biomarkers, cognitive screening tools will play an integral role in the early detection of impairment.

Memory Impairment Screening Tool Gains FDA Clearance

Wednesday, January 25, 2017—The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults…

High Levels of Aluminum Found in Brain Tissue of Individuals with Familial Alzheimer’s Disease

Thursday, January 12, 2017—A British study has found extremely high levels of aluminum in the tissue of brains of individuals with familial Alzheimer’s disease. Using fluorescence microscopy to id…

Neuronix Reveals Data Suggesting Non-invasive TMS Device Improves Cognitive Performance in Alzheimer’s Disease

Thursday, January 05, 2017—New findings suggest that an investigational device that combines transcranial magnetic stimulation (TMS) with cognitive training may improve cognitive performance in ind…

Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis

Wednesday, December 21, 2016—Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis Acadia Pharmaceuticals has unveiled positive top-line resu…

Saliva Test May Detect Alzheimer’s Disease

Tuesday, November 22, 2016—A new saliva test developed by Aurin Bitech could serve as a diagnostic marker for Alzheimer’s disease, according to new findings published the Journal of Alzheimers Dis…

Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website

Thursday, October 27, 2016—The Alzheimer’s Drug Discovery Foundation (ADDF) has relaunched, its brain health and dementia prevention website. Specifically, the site offers ra…

Tramiprosate Shows Gene-Dose Effect in Alzheimer’s Patients with APOE4

Tuesday, October 25, 2016—New phase 3 findings suggest that the investigational amyloid-targeted agent tramiprosate may particularly effective for patients with ε4 alleles of apolipoprotein E (…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.